Prêmio GlaxoSmithKline

O Prêmio GlaxoSmithKline (em inglês: GlaxoSmithKline Prize and Lecture) é concedido pela Royal Society "por contribuições originais às ciências médica e veterinária publicadas dentro de dez anos da data do prêmio".[1] Patrocinada pela GlaxoSmithKline, a medalha é acompanhada de um montante de £ 2 500. A medalha foi concedida a primeira vez em 1980 para César Milstein.[1]



Ano Nome Motivo Notas
1980 César Milstein "in recognition of his pioneering the production of monoclonal antibodies from hybrid cell lines and initiating their application worldwide in many fields of biology and medicine"
1982 Hans Walter Kosterlitz "in recognition of his studies of the action of opiates and the discovery of the enkephalins"
1984 Edward Raymond Andrew, James M. S. Hutchison, John Mallard e Peter Mansfield "in recognition of their development of NMR imaging as a diagnostic tool in medicine"
1986 Donald Metcalf e Leo Sachs "in recognition of their discovery of factors which regulate growth and differentiation in normal and leukaemic blood-forming tissue"
1988 Louis Martens Kunkel "in recognition of his achievement in identifying by novel techniques of reverse genetics the biochemical abnormality responsible for Duchenne/Becker muscular dystrophy as being the absence of a previously unknown protein, dystrophin"
1990 Philippa Marrack e John Kappler "in recognition of their seminal contributions to T-cell biology, which include the characterisation of the T-cell receptor; the demonstration that self-tolerance is caused by clonal elimination in the thymus; and the discovery that bacterial toxins act as 'superantigens'"
1992 Paul Nurse "in recognition of his seminal contributions to the understanding of the molecular basis of regulation of the eukaryotic cycle"
1994 David James Purslove Barker "in recognition of his singularly novel and important contributions to our understanding of the causes of a number of the major diseases of later life (cardiovascular disease, obstructive airways disease and diabetes) by demonstrating that their origins may lie in fetal nutrition and in growth in utero and during infancy"
1996 Charles Weissmann "in recognition of his work on prion diseases which lead to the remarkable advances in understanding the molecular biology of spongiform encephalopathies"
1998 Gillian Bates e Stephen Davies "in recognition of their discovery of the cause of Huntington's Disease, a dominantly inherited, late onset, fatal neurodegenerative disease"
2000 David MacLennan "in recognition of his work on calcium regulatory proteins, particularly in the understanding of malignant hyperthermia (MH), central core disease (CCD), Brody disease and phospholamban, and applying his knowledge of the gene in MH to develop accurate diagnosis of disease in pigs. In addition to its valuable veterinary application, this work represents a particularly good example of the way in which basic science has been developed to the point at which it is widely applied"
2003 Michael Neuberger "in recognition of his work on resolving the molecular mechanism of somatic antibody diversification, a key feature of immune response, with consequences reaching far beyond immunology to DNA instability and cancer"
2005 Nicholas White "for his outstanding work on the treatment and prevention of serious diseases within the developing world" [2]
2007 Mark Pepys "for his excellent work as a clinical scientist who has identified specific proteins as new therapeutic targets and developed novel drugs with potential use in amyloidosis, Alzheimer's disease and cardiovascular disease" [3]
2010 Stephen Craig West "in recognition of his pioneering work on the molecular mechanisms of genetic recombination and DNA repair and their relation to tumorigenesis" [4]
2012 Adrian Bird "for his outstanding contributions in the field of epigenetics, especially DNA methylation and its role in development and disease." [5]
2014 Nicholas Lydon "for the development of the drug imatinib, a targeted tyrosine kinase inhibitor that has transformed the treatment of chronic myelogenous leukaemia (CML) and is a paradigm for cancer drug discovery." [6]
2016 Andrew Hattersley "for his work on genetic and physiological studies of patients with common subtypes of monogenic diabetes" [7]